TOVX - מכפיל P/S Synthetic Biologics

P/S multiple fluctuations on the GURU.Markets platform demonstrate that Theriva Biologics, Inc. (TOVX) quotes remain independent of macroeconomics, as the company's success relies on the progress of adenoviral drug trials. High patent margins ensure scalability, while asset value depends on patient survival rates and technology protection. The value of 21.80 indicates the current level of the business's market valuation.
Synthetic Biologics (TOVX) - פילוחי מדדים ודוחות פיננסיים

Investors assess the operational strength of assets through the price-to-sales ratio, where low values signal undervaluation and inflated figures indicate speculative risk. By analyzing changes in the P/S multiple, one can correlate the business value of Theriva Biologics, Inc. (TOVX) with the efficiency of its academic R&D approach and the costs of PhD specialists, thereby determining the company's fundamental stability.